BACKGROUND: The USA300 methicillin-resistant Staphylococcus aureus (MRSA) strain, which initially emerged as a cause of community-associated infections, has recently become an important pathogen in healthcare-associated infections (HAIs). However, its impact on patient outcomes has not been well studied. We evaluated patients with invasive MRSA infections to assess differences in outcomes between infections caused by USA100 and those caused by USA300. METHODS: Population-based data for invasive MRSA infections were used to identify 2 cohorts: (1) nondialysis patients with central line-associated bloodstream infections (CLABSIs) and (2) patients with community-onset pneumonia (PNEUMO) during 2005-2007 from 6 US metropolitan areas. Medical records of patients with confirmed MRSA USA100 or USA300 infection were reviewed. Logistic regression and, when appropriate, survival analysis was performed to evaluate mortality, early and late complications, and length of stay. RESULTS: A total of 236 and 100 patients were included in the CLABSI and PNEUMO cohorts, respectively. USA300 was the only independent predictor of early complications for PNEUMO patients (odds ratio [OR], 2.6; P = .02). Independent predictors of CLABSI late complications included intensive care unit (ICU) admission before MRSA culture (adjusted OR [AOR], 2.1; P= .01) and Charlson comorbidity index (AOR, 2.6; P = .003), but not strain type. PNEUMO patients were significantly more likely to die if they were older (P = .02), black (P < .001), or infected with USA100 strain (P = .02), whereas those with CLABSI were more likely to die if they were older (P < .001), had comorbidities (P < .001), or had an ICU admission before MRSA culture (P = .001). CONCLUSIONS: USA300 was associated with early complications in PNEUMO patients. However, it was not associated with mortality for either PNEUMO or CLABSI patients. Concerns regarding higher mortality from HAIs caused by USA300 may not be warranted.
BACKGROUND: The USA300 methicillin-resistant Staphylococcus aureus (MRSA) strain, which initially emerged as a cause of community-associated infections, has recently become an important pathogen in healthcare-associated infections (HAIs). However, its impact on patient outcomes has not been well studied. We evaluated patients with invasive MRSA infections to assess differences in outcomes between infections caused by USA100 and those caused by USA300. METHODS: Population-based data for invasive MRSA infections were used to identify 2 cohorts: (1) nondialysis patients with central line-associated bloodstream infections (CLABSIs) and (2) patients with community-onset pneumonia (PNEUMO) during 2005-2007 from 6 US metropolitan areas. Medical records of patients with confirmed MRSA USA100 or USA300infection were reviewed. Logistic regression and, when appropriate, survival analysis was performed to evaluate mortality, early and late complications, and length of stay. RESULTS: A total of 236 and 100 patients were included in the CLABSI and PNEUMO cohorts, respectively. USA300 was the only independent predictor of early complications for PNEUMO patients (odds ratio [OR], 2.6; P = .02). Independent predictors of CLABSI late complications included intensive care unit (ICU) admission before MRSA culture (adjusted OR [AOR], 2.1; P= .01) and Charlson comorbidity index (AOR, 2.6; P = .003), but not strain type. PNEUMO patients were significantly more likely to die if they were older (P = .02), black (P < .001), or infected with USA100 strain (P = .02), whereas those with CLABSI were more likely to die if they were older (P < .001), had comorbidities (P < .001), or had an ICU admission before MRSA culture (P = .001). CONCLUSIONS:USA300 was associated with early complications in PNEUMO patients. However, it was not associated with mortality for either PNEUMO or CLABSI patients. Concerns regarding higher mortality from HAIs caused by USA300 may not be warranted.
Authors: Courtney R Murphy; Lyndsey O Hudson; Brian G Spratt; Kristen Elkins; Leah Terpstra; Adrijana Gombosev; Christopher Nguyen; Paul Hannah; Richard Alexander; Mark C Enright; Susan S Huang Journal: Infect Control Hosp Epidemiol Date: 2013-04-22 Impact factor: 3.254
Authors: Lilly Cheng Immergluck; Sarah W Satola; Shabnam Jain; Courtney McCracken; J Renee' Watson; Trisha Chan; Traci Leong; Edward Gottlieb; Robert C Jerris Journal: Am J Infect Control Date: 2013-02-20 Impact factor: 2.918
Authors: Manuela Buonanno; Brian Ponnaiya; David Welch; Milda Stanislauskas; Gerhard Randers-Pehrson; Lubomir Smilenov; Franklin D Lowy; David M Owens; David J Brenner Journal: Radiat Res Date: 2017-02-22 Impact factor: 2.841
Authors: Maria Souli; Felicia Ruffin; Seong-Ho Choi; Lawrence P Park; Shengli Gao; Nicholas Christopoulos Lent; Batu K Sharma-Kuinkel; Joshua T Thaden; Stacey A Maskarinec; Lisa Wanda; Jonathan Hill-Rorie; Bobby Warren; Brenda Hansen; Vance G Fowler Journal: Clin Infect Dis Date: 2019-11-13 Impact factor: 9.079
Authors: Sonya L Heltshe; Lisa Saiman; Elena B Popowitch; Melissa B Miller; Margaret Kloster; Valeria Thompson; Thomas W Ferkol; Wynton C Hoover; Michael S Schechter; Marianne S Muhlebach Journal: J Pediatric Infect Dis Soc Date: 2014-06-09 Impact factor: 3.164
Authors: Karla D Passalacqua; Sarah W Satola; Emily K Crispell; Timothy D Read Journal: Antimicrob Agents Chemother Date: 2012-07-30 Impact factor: 5.191
Authors: Manuela Buonanno; Gerhard Randers-Pehrson; Alan W Bigelow; Sheetal Trivedi; Franklin D Lowy; Henry M Spotnitz; Scott M Hammer; David J Brenner Journal: PLoS One Date: 2013-10-16 Impact factor: 3.240